301033.SHE Medprin Regenerative Medical Technologies Co. Ltd.
- Market cap
- CNY 3.58B
- P/E
- 28.0x
- P/B
- 4.15x
- ROE
- 14.0%
- Dividend yield
- 1.11%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301033.SHE undervalued?
Graham number301033.SHE trades 127.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Medprin Regenerative Medical Technologies Co. Ltd. fundamental analysis
No fundamental analysis for Medprin Regenerative Medical Technologies Co. Ltd. yet.
Medprin Regenerative Medical Technologies Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Medprin Regenerative Medical Technologies Co. Ltd.
Medprin Regenerative Medical Technologies Co., Ltd. engages in the research and development, manufacture, and sale of implantable medical devices in China and internationally. The company offers artificial dura mater patches, craniofacial repair and fixation systems, and absorbable regenerative oxidation for neurosurgery meningeal repair, skull repair fixation and rapid hemostasis, etc. It also offers ReDura, a Synthetic Dural Substitute; NeoDura, a novel dural patch; Recran…
Full company profileMedprin Regenerative Medical Technologies Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Medprin Regenerative Medical Technologies Co. Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 113M | 124M | 154M | 195M | 231M | 278M | 369M | 392M |
| Gross Profit | 96.9M | 103M | 127M | 164M | 189M | 221M | 296M | 315M |
| Operating Income | 25.1M | 34.9M | 37.5M | 33.1M | 45.2M | 87.0M | 127M | 140M |
| EBITDA | 36.2M | 40.4M | 60.3M | 56.9M | 75.6M | 121M | 154M | 138M |
| Net Income | 27.7M | 37.0M | 44.7M | 35.9M | 40.9M | 78.9M | 113M | 121M |
| EPS | 0.56 | 0.75 | 0.68 | 0.54 | 0.62 | 1.19 | 1.69 | 1.78 |
| Balance Sheet | ||||||||
| Total Assets | 340M | 455M | 747M | 745M | 787M | 799M | 895M | 957M |
| Total Liabilities | 37.3M | 117M | 171M | 142M | 151M | 99.6M | 97.4M | 92.8M |
| Shareholders' Equity | 299M | 334M | 572M | 603M | 636M | 700M | 798M | 864M |
| Cash & Short-term Investments | 28.4M | 11.7M | 10.4M | 45.0M | 26.7M | 57.5M | 74.0M | 124M |
| Cash Flow | ||||||||
| Operating Cash Flow | 31.3M | 33.9M | 66.5M | 48.3M | 108M | 116M | 140M | - |
| Capital Expenditure | 36.7M | 61.6M | 153M | 136M | 40.1M | 33.2M | 23.8M | 45.1M |
| Free Cash Flow | -5.44M | -27.7M | -86.2M | -87.6M | 67.6M | 83.2M | 116M | 74.0M |
| Ratios | ||||||||
| ROE | 9.3% | 11.1% | 7.8% | 6.0% | 6.4% | 11.3% | 14.2% | 14.0% |
| ROA | 8.1% | 8.1% | 6.0% | 4.8% | 5.2% | 9.9% | 12.6% | 12.6% |
| Net Profit Margin | 24.4% | 29.9% | 29.1% | 18.4% | 17.7% | 28.3% | 30.7% | 30.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Medprin Regenerative Medical Technologies Co. Ltd. dividends
- Dividend yield
- 1.11%
- Forward dividend
- 0.70 CNY
- Payout ratio
- 35.1%
- Ex-dividend date
- Jun 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 39.7M | 0.59 | 35.1% |
| 2024 | CNY 27.1M | 0.41 | 34.4% |
| 2023 | CNY 15.3M | 0.23 | 37.4% |
| 2022 | CNY 8.05M | 0.12 | 22.4% |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Medprin Regenerative Medical Technologies Co. Ltd.
- Insiders 45.17%
- Institutions 13.83%
- Public & others 41.00%
- Shares outstanding 67.6M
- Free float 35.4M
Medprin Regenerative Medical Technologies Co. Ltd. company profile
- Company name
- Medprin Regenerative Medical Technologies Co. Ltd.
- Ticker
- 301033.SHE
- ISIN
- CNE100004NB8
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 447
- Fiscal year end
- December
- Address
- No. 3 Yayingshi Road, Guangzhou, China, 510700
- Phone
- 86 20 3229 6118
- Website
- medprin.com
About Medprin Regenerative Medical Technologies Co. Ltd.
Medprin Regenerative Medical Technologies Co., Ltd. engages in the research and development, manufacture, and sale of implantable medical devices in China and internationally. The company offers artificial dura mater patches, craniofacial repair and fixation systems, and absorbable regenerative oxidation for neurosurgery meningeal repair, skull repair fixation and rapid hemostasis, etc. It also offers ReDura, a Synthetic Dural Substitute; NeoDura, a novel dural patch; Recranio, a Cranio-Maxillofacial repair system; and StypCel, an Absorbable Hemostat; Immiseal, a dural sealant system; and 3D bioprinting applications serving patients internationally. Medprin Regenerative Medical Technologies Co., Ltd. was founded in 2008 and is headquartered in Guangzhou, China.
Medprin Regenerative Medical Technologies Co. Ltd. management
5- Mr. Jianhua WangGM & Director · born 1968
- Ms. Yahong LuoCFO, Deputy GM & Non-Independent Director · born 1968
- Ms. Xiaoyan LongDeputy GM, Board Secretary & Non-Independent Director · born 1984
- Ms. Yuanyuan LiDeputy General Manager · born 1982
- Zhiguo SunAccounting Supervisor